earnings
confidence high
sentiment positive
materiality 0.75
GeneDx achieves Q3 2024 profitability with $1.2M adjusted net income, raises FY guidance
GeneDx Holdings Corp.
2024-Q3 EPS reported
-$2.17
revenue$209,810,000
- Revenue $76.6M (+52% YoY); exome/genome revenue $60.0M (+77% YoY).
- Adjusted net income $1.2M (first profitable quarter); GAAP net loss $8.3M.
- Adjusted gross margin 64%, up from 48% YoY.
- FY 2024 revenue guidance raised to $284–290M (prev. $255–265M).
- Cash use improved 88% YoY to $5.0M; $117.4M cash as of Sept. 30, 2024.